N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
Subscribe To Our Newsletter & Stay Updated
